Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Clover Health Is Telling Investors a Story, But Are They Listening

By Chris Markoch, InvestorPlace Contributor

Clover Health’s CEO is telling investors everything they need to know about the short-term fortunes of CLOV stock. The only question is are they listening?  

A Bullish Outlook on Ocugen Is a Bearish Outlook on the Pandemic

By Chris Markoch, InvestorPlace Contributor

For OCGN stock to justify its present valuation, Covaxin will have to generate a significant amount of North American sales. If it doesn’t the stock has a long way to fall.  

Skillz Stock Requires Patience

By Chris Markoch, InvestorPlace Contributor

SKLZ stock may have a path to trade significantly higher. The question is whether investors will be patient enough to wait for the growth.  

7 High-Quality REITs to Buy Now for the Current Real Estate Market

By Chris Markoch, InvestorPlace Contributor

The real estate market has taken off in 2021. Here are seven high-quality REITs that can help you take advantage of this explosive growth.

Lucid Motors Stock Deserves Time and Patience, but Not Too Much

By Chris Markoch, InvestorPlace Contributor

Lucid bulls refer to the company as a significant rival to Tesla. They may be right, but for LCID stock to reward investors, the company has to hit its targets.  

Load More